CoWin Biosciences Closes $36 Million Financing for Reagents Business

CoWin Biosciences, a Beijing biological reagent company, closed a $36 million financing led by Addor Capital with Green Pine Capital Partners and Share Capital participating. Established in 2007, CoWin Biosciences provides high quality biology reagents for life science research and molecular diagnostics. In July, the company's novel SARS-CoV-2  Fast Nucleic Acid Detection Kit was approved for use in the US. The kit detects the virus' nucleocapsid and ORF1ab genes in oropharyngeal swabs. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.